Name: Inhibikase Therapeutics, Inc. (IKT) Financial Statements
Creator: FinSpry

Inhibikase Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Inhibikase Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.26	0.12	3.10	0.70
Cost of Revenue	17.21	13.62	12.03	11.36	0.89
Gross Profit	-17.21	-13.36	-11.91	-8.26	-0.20
Operating Expenses
Research & Development	17.21	13.62	12.03	11.36	0.00
Selling, General & Administrative	11.38	6.73	6.22	6.51	2.62
Operating Expenses	11.38	20.09	6.22	14.77	2.62
Operating Income	-28.59	-20.09	-18.13	-14.77	-2.82
Other Income/Expense
Interest Income	1.07	1.06	0.07	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.02	-0.03
Other Income/Expense	1.07	0.10	0.00	0.00	0.00
Income
Income Before Tax	-27.52	-19.03	-18.05	-14.79	-2.85
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-27.52	-19.03	-18.05	-14.79	-2.85
Net Income - Continuous Operations	-27.52	-19.03	-18.05	-14.79	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-28.56	-19.91	-18.12	-14.77	0.00
EBIT	-28.59	-20.09	-18.13	-14.77	-2.82
Depreciation & Amortization	0.03	0.18	0.01	0.00	0.00
Earnings Per Share
Basic EPS	-	-3.00	-4.00	-5.00	-2.00
Diluted EPS	-	-3.00	-4.00	-5.00	-2.00
Basic Shares Outstanding	89.18	6.03	4.22	3.03	1.37
Diluted Shares Outstanding	89.18	6.03	4.22	3.03	1.37